Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556775 · ClinicalTrials.gov registry record
Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia
A clinical trial, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 16
- Enrollment target
NCT02556775 is a clinical trial that has completed, run by Baxalta now part of Shire. The registered enrollment target is 16 participants.
The verdict
NCT02556775 has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
The purpose of this registry is to acquire safety data (including assessment of anti-rHuPH20 antibodies), regarding the course and outcome of pregnancy in women ever treated with HYQVIA. Development of the fetus/infant at birth and for the first 2 years will also be followed.
Interventions
- BIOLOGICAL A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment
- BIOLOGICAL HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-12-04 |
| Est. Completion | 2019-12-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02556775
The ClinicalTrials.gov registry entry for NCT02556775 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment is the first listed.
NCT02556775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02556775 about?
NCT02556775 is a clinical study titled "Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia". The purpose of this registry is to acquire safety data (including assessment of anti-rHuPH20 antibodies), regarding the course and outcome of pregnancy in women ever treated with HYQVIA. Development of the fetus/infant at birth and for the first 2 years will also be followed.
What is the current status of trial NCT02556775?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2015-12-04. Estimated completion is 2019-12-17.
What interventions are being tested in trial NCT02556775?
The interventions under investigation include: A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment (BIOLOGICAL), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] (BIOLOGICAL).
Who is sponsoring clinical trial NCT02556775?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.